Bone Therapeutics’ ALLOB Achieves Primary Endpoint in Delayed-Union Fracture Study
Bone Therapeutics reported all patients met the primary endpoint in the U.S. Phase I/IIA study of ALLOB® allogeneic bone-cell therapy in the treatment of delayed-union fractures. Sep 14, 2018